Synthetic Design Lab Debuts First Logic-Gated ADC at AACR 2026, Showing Over 10X Boost in Cancer Cell Killing
Synthetic Design Lab has unveiled a bold new direction in the field of biologic therapeutics with the introduction of its SYNTHBODY™ platform—a technology that could redefine how drugs interact with disease at the molecular level. Presented for the first time at the American Association for Cancer Research (AACR) Annual Meeting 2026, the company’s preclinical data highlights a new class of “smart drugs”: protein therapeutics embedded with multi-layered logic systems that actively adapt their behavior based on the biological environment they encounter.
This approach represents a significant departure from conventional antibody-based therapies. Traditional protein drugs, including monoclonal antibodies and antibody-drug conjugates (ADCs), typically operate in a passive manner. They bind to a single target (or, in more advanced cases, two targets) and either inhibit or activate a biological process. While these therapies have revolutionized treatment for certain cancers, their effectiveness is often limited by the availability of highly specific and abundantly expressed targets on tumor cells.
SYNTHBODY™ seeks to overcome these limitations by introducing programmable behavior into protein therapeutics. Rather than relying on a single molecular interaction, these engineered constructs integrate multiple binding domains arranged in a precise geometric configuration. This allows them to recognize combinations of targets—what the company refers to as “Synthetic Targets”—and respond dynamically. In essence, SYNTHBODY™ molecules function more like molecular processors than static drugs, using built-in logic gates to determine when and how to bind, internalize, and deliver their therapeutic payload.
At the core of this innovation is the concept of logic-gated biology. The SYNTHBODY™ architecture incorporates multiple layers of decision-making mechanisms, including “AND” gates that require the presence of multiple targets before activation, “AND-BETTER” logic that enhances specificity and selectivity, and “MULTIPLIER” functions that amplify therapeutic effects when optimal conditions are met. These features enable the drug to distinguish more effectively between healthy and diseased cells, potentially improving both efficacy and safety.
According to the company’s founder and CEO, Daniel S. Chen, M.D., Ph.D., this capability represents a fundamental shift in drug design. Instead of tailoring treatments to specific patient populations based on biomarkers—a cornerstone of precision medicine—adaptive therapeutics like SYNTHBODY™ could one day reduce the need for such matching. If a drug can intelligently adjust its behavior in response to different biological contexts, it may be able to treat a broader range of patients more effectively.
The preclinical data presented at AACR 2026 provides early validation of this concept. In studies targeting multiple myeloma, Synthetic Design Lab engineered a SYNTHBODY™ construct that simultaneously engages three antigens: BCMA, GPRC5D, and CD38. Individually, these targets do not exhibit the high expression levels or specificity seen in well-known targets like HER2. However, when combined within the SYNTHBODY™ framework, they form a synthetic composite target with enhanced selectivity and functional relevance.
This combinatorial targeting approach yielded striking results. In head-to-head comparisons with existing therapies, the SYNTHBODY™ molecule demonstrated more than 30-fold greater internalization into cancer cells compared to a BCMA-targeting antibody. When linked to a cytotoxic payload, it achieved over 80-fold greater potency in vitro. Importantly, these effects were observed across cell lines with varying levels of target expression, suggesting robustness in diverse tumor environments.
Another notable finding was the molecule’s ability to overcome a known resistance mechanism. Soluble BCMA, which can circulate in the bloodstream and interfere with drug binding, often reduces the effectiveness of BCMA-targeted therapies. The SYNTHBODY™ construct maintained its activity even in the presence of clinically relevant levels of soluble BCMA, indicating a potential advantage in overcoming treatment resistance.
In vivo studies further reinforced these findings. In mouse tumor models, the SYNTHBODY™ therapeutic achieved at least a tenfold increase in efficacy compared to an IgG-based ADC comparator. Additionally, the platform demonstrated tunable pharmacokinetics similar to conventional antibodies, suggesting that these complex molecules can be engineered to behave predictably in the body.
Beyond multiple myeloma, the platform has shown promising early results in other cancer types. A SYNTHBODY™ construct targeting non-Hodgkin’s lymphoma exhibited similar performance enhancements, and the company is actively expanding its pipeline into solid tumors. Using its high-throughput SYNTHBODY ENGINE™ system, Synthetic Design Lab can rapidly design, test, and optimize new constructs, enabling broad applicability across oncology and potentially beyond.
One of the most compelling aspects of the SYNTHBODY™ platform is its ability to address a longstanding challenge in cancer therapy: the scarcity of ideal targets. Many tumors do not express a single protein at levels sufficient for effective targeting. This has limited the reach of ADCs and other targeted therapies. By combining multiple lower-expression targets into a unified synthetic target, SYNTHBODY™ effectively creates new opportunities where none previously existed.
This strategy could significantly expand the range of treatable cancers. While therapies targeting HER2 have achieved notable success in certain breast cancers, HER2 itself is an exception rather than the rule. Most tumors lack such highly specific markers. SYNTHBODY™’s combinatorial approach offers a way to bypass this limitation, potentially bringing targeted therapy to a much wider patient population.
From a development and manufacturing perspective, the platform also appears promising. The company reports that optimized SYNTHBODY™ constructs exhibit strong manufacturability in Chinese hamster ovary (CHO) cells, the industry standard for biologics production. They also demonstrate favorable developability characteristics, including stability and scalability, which are critical for clinical translation.
Ramesh Baliga, Ph.D., Chief Scientific Officer and co-founder of Synthetic Design Lab, emphasized the importance of structural design in enabling these capabilities. By precisely controlling the geometry and biophysical properties of the molecule, the team can unlock emergent behaviors that are not possible with traditional antibody formats. This level of control allows for fine-tuning of binding interactions, spatial arrangement, and functional outputs, all within a single therapeutic construct.
While the data presented are still preclinical, the implications are far-reaching. If validated in human trials, SYNTHBODY™ could represent a new paradigm in drug development—one where therapeutics are not just targeted, but intelligent and adaptive. Such drugs could potentially improve outcomes, reduce side effects, and simplify treatment strategies by eliminating the need for highly specific patient selection.
Of course, significant challenges remain. Translating complex engineered proteins from the laboratory to the clinic involves rigorous testing for safety, efficacy, and manufacturability. Regulatory pathways for such novel constructs may also require adaptation. However, the early results suggest that these hurdles may be worth overcoming.
In summary, Synthetic Design Lab’s SYNTHBODY™ platform introduces a fundamentally new approach to biologic therapeutics. By embedding logic and adaptability into protein drugs, the company aims to move beyond the limitations of conventional targeting strategies. With demonstrated improvements in internalization, potency, and efficacy across multiple cancer models, the technology holds promise for transforming how diseases are treated. As development progresses, it will be closely watched as a potential breakthrough in the evolution of precision—and possibly autonomous—medicine.
About Synthetic Design Lab
Synthetic Design Lab is built to revolutionize antibody-drug conjugates (ADCs) and biologic therapeutics with its novel and proprietary SYNTHBODY™ therapeutic protein platform. Through a focus on control of biophysics, architecture, geometry, and biologically determined patterns and protein communities, the platform is engineered to optimize targeted payload delivery ≥10x compared to current ADCs, potentially improving upon the efficacy, safety, and overall versatility of earlier ADCs.
